Sarah J Roberts-Thomson

Prof. Sarah J Roberts-Thomson

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Nature Reviews Cancer
Verified
Journal Article
Closed access
GMGregory Monteith
Gregory Monteith
DMDamara McAndrew
Damara McAndrew
Helen M. FaddyHelen M. Faddy
Helen M. Faddy
SRSarah J Roberts-Thomson
Sarah J Roberts-Thomson

7 April 2017 in Nature Reviews Cancer
Verified
Journal Article
Closed access
GMGregory Monteith
Gregory Monteith
Natalia PrevarskayaNatalia Prevarskaya
Natalia Prevarskaya
SRSarah J Roberts-Thomson
Sarah J Roberts-Thomson

1 September 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
GMGregory Monteith
Gregory Monteith
FDFelicity Davis
Felicity Davis
SRSarah J Roberts-Thomson
Sarah J Roberts-Thomson
Increases in intracellular free Ca2+ play a major role in many cellular processes. The deregulation of Ca2+ signaling is a feature of a variety of diseases, and modulators of Ca2+ signaling are used to treat conditions as diverse as hypertension to pain. The Ca2+ signal also plays a role in processes important in cancer, such as proliferation and migration. Many studies in cancer have identified alterations in the expression of proteins involved in the movement of Ca2+ across the plasma membrane and subcellular organelles. In some cases, these Ca2+ channels or pumps are potential therapeutic targets for specific cancer subtypes or correlate with prognosis.

1 May 2013 in Oncogene
Verified
Journal Article
Open access
PDF file
FDFelicity Davis
Felicity Davis
IAIman Azimi
Iman Azimi
RFR A Faville
R A Faville
APA A Peters
A A Peters
KJK Jalink
K Jalink
GMGregory Monteith
Gregory Monteith
Signals from the tumor microenvironment trigger cancer cells to adopt an invasive phenotype through epithelial–mesenchymal transition (EMT). Relatively little is known regarding key signal transduction pathways that serve as cytosolic bridges between cell surface receptors and nuclear transcription factors to induce EMT. A better understanding of these early EMT events may identify potential targets for the control of metastasis. One rapid intracellular signaling pathway that has not yet been explored during EMT induction is calcium. Here we show that stimuli used to induce EMT produce a transient increase in cytosolic calcium levels in human breast cancer cells. Attenuation of the calcium signal by intracellular calcium chelation significantly reduced epidermal growth factor (EGF)- and hypoxia-induced EMT. Intracellular calcium chelation also inhibited EGF-induced activation of signal transducer and activator of transcription 3 (STAT3), while preserving other signal transduction pathways such as Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation. To identify calcium-permeable channels that may regulate EMT induction in breast cancer cells, we performed a targeted siRNA-based screen. We found that transient receptor potential-melastatin-like 7 (TRPM7) channel expression regulated EGF-induced STAT3 phosphorylation and expression of the EMT marker vimentin. Although intracellular calcium chelation almost completely blocked the induction of many EMT markers, including vimentin, Twist and N-cadherin, the effect of TRPM7 silencing was specific for vimentin protein expression and STAT3 phosphorylation. These results indicate that TRPM7 is a partial regulator of EMT in breast cancer cells, and that other calcium-permeable ion channels are also involved in calcium-dependent EMT induction. In summary, this work establishes an important role for the intracellular calcium signal in the induction of EMT in human breast cancer cells. Manipulation of calcium-signaling pathways controlling EMT induction in cancer cells may therefore be an important therapeutic strategy for preventing metastases.

1 October 2010 in Cell
Verified
Journal Article
Closed access
MFMingye Feng
Mingye Feng
DGDesma M. Grice
Desma M. Grice
Helen M. FaddyHelen M. Faddy
Helen M. Faddy
NNNguyen Nguyen
Nguyen Nguyen
SLSharon Leitch
Sharon Leitch
RRRajini Rao
Rajini Rao

1 March 2011 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
DMDamara McAndrew
Damara McAndrew
DGDesma M. Grice
Desma M. Grice
APAmelia A. Peters
Amelia A. Peters
FDFelicity Davis
Felicity Davis
TSTeneale Stewart
Teneale Stewart
GMGregory Monteith
Gregory Monteith
The entry of calcium into the mammary epithelial cell from the maternal plasma (i.e., calcium influx mechanisms) during lactation is poorly understood. As alterations in calcium channels and pumps are a key feature of some cancers, including breast cancer, understanding these calcium influx pathways may have significance beyond mammary biology. We show that the store-operated calcium influx protein, Orai1, is increased during lactation whereas the Orai1 activator Stim1, but not Stim2, is downregulated. Stim2 siRNA reduced basal calcium levels in a lactation model. Our results suggest that calcium influx is remodeled in mammary epithelial cells during lactation, with calcium influx increased through Orai1, activated by Stim2. Breast cancer cell lines had increased levels of ORAI1. ORAI1 siRNA in breast cancer cells reduced store-operated calcium entry and remodeled the calcium influx associated with invasive stimuli. Analysis of microarray data from 295 breast cancers showed that the transcriptional breast cancer subtype with the poorest prognosis (basal) was associated with an altered relationship between the ORAI1 regulators STIM1 and STIM2, and that women with breast cancers with STIM1high/STIM2low tumors had a significantly poorer prognosis. Our studies show that during lactation there is a remodeling in the nature of calcium influx and that alteration in the ORAI1 influx pathway may be a feature of some breast cancers, particularly those with the poorest prognosis. Our studies suggest that this pathway may be a novel therapeutic target for breast cancer treatment in these women. Mol Cancer Ther; 10(3); 448–60. ©2011 AACR.